About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, April 11th, 2013

The QualityStocks
Daily Stock List

graphic
graphic

Axxess Unlimited, Inc. (AXXU)

Chatter Box Stocks, TerrificPennyStocks, AwesomeStocks, SquawkBoxStocks, PennyStocks24, and StockExploder reported this week on Axxess Unlimited, Inc. (AXXU), and we highlight the Company as "One to Watch" this week here at the QualityStocks Daily Newsletter.

Axxess Unlimited provides actionable, next-generation business intelligence for a wide spectrum of businesses and organizations. They are a provider of information-driven business solutions via interactive marketing, interactive technologies, application and product development, customer relationship management (CRM), business intelligence, portals and collaboration, as well as infrastructure solutions. Axxess Unlimited has their headquarters in Scottsdale, Arizona, and they have an office in Los Angeles, California.

Axxess Unlimited is the holding company for the Axxess family of companies. This includes both vertically integrated operating businesses and horizontally integrated companies. Each is supported by a common software technology – the proprietary Axxess RISE Platform.
 
The Axxess Ad Tracker, launched in May of 2012, leads their digital marketing platform. Ad Tracker is the first acquisition-focused ad tracking technology that allows companies to track responses across multiple advertising mediums. The Company's tightly integrated proprietary technology platform enables companies to manage all of their digital marketing efforts easily while reaching, engaging and gaining knowledge about their customers.

Axxess Unlimited's companies include Axxess Digital (AxxuD). AxxuD is an interactive digital agency company. AxxuD represents a new breed of marketing partner, blending strategy, creative services, and technology, media and data offerings. They rely heavily on the core logic of the Axxess Unlimited RISE platform.

Their companies also include Axxess Apps (AxxuA). AxxuA is a software development company that focuses on Enterprise Applications, Custom Applications, Cloud Applications, and Mobile Applications.

Axxess Unlimited's companies additionally include Axxess Brands (AxxuB). AxxuB is a marketer and manufacturer of specialty brands in better-for-you and indulgent categories under an array of Company owned and licensed brand names.  AxxuB licenses leading brands and provides outsource management.

Yesterday, Axxess Apps (AxxuA) announced that they have developed the first Android ignition interlock mobile application. This is the Axxess Interlock Reporting (Axxess AIR™) Android app. The Android app is a companion to the Apple app for the iPad and iPhone that launched in November 2012.

Today, Axxess Digital (AxxuD) announced that the Gospel Association of India (GAI) has engaged them to raise donations and awareness on the Web.  Axxess Digital will lead GAI's online marketing efforts to further the organization's mission of serving children in need of hope and a home. This is while promoting moral and biblical values, providing spiritual guidance, and educating them to become effective leaders of the future.

We have Axxess Unlimited, Inc. (AXXU) in our sightlines as "One to Watch" this week here at the QualityStocks Daily Newsletter.

Axxess Unlimited, Inc. (AXXU), closed Thursday's trading session at $0.444, down 17.78%, on 282,930 volume with 142 trades. The average volume for the last 60 days is 14,976 and the stock's 52-week low/high is $0.40/$1.75.

ERF Wireless, Inc. (ERFB)

FeedBlitz and Pumps and Dumps reported previously on ERF Wireless, Inc. (ERFB), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Headquartered in League City, Texas, ERF Wireless, Inc. is a foremost provider of enterprise-class wireless and broadband products and services. ERF Wireless is the parent company of Energy Broadband, Inc., ERF Enterprise Network Services, ERF Bundled Wireless Services, ERF Wireless Messaging Services, and ERF Network Services. The Company specializes in supplying wireless and broadband product and service solutions to enterprise, commercial and residential clients on a regional, national as well as worldwide basis.  

ERF Wireless provides high quality broadband services and basic communications services to residential, commercial, oil and gas, banking, healthcare and educational customers in areas that are traditionally unable to receive these services. The Company is also a complete solutions provider to other enterprise customers. They provide these customers with a broad spectrum of communications services. These services include high-speed broadband and Voice over Internet Protocol (VoIP) telephone and facsimile service.

Their Energy Broadband Division provides a unique wireless broadband product and service offering to major oilfield producers and service providers. This includes secure, cost-effective data transmission to and from drilling rigs and production wells across North America. The Enterprise Network Services Division provides banks and financial institutions with secure, next generation data connectivity. This division also provides the turnkey design and implementation of secure wireless broadband networks for enterprise-class applications.

The Bundled Wireless Services Division provides wireless broadband Internet connectivity, VoIP telephone service and many other traditional ISP services. The Wireless Messaging Services Division manufactures and supplies high-power wireless infrastructure equipment to the paging and mobile industry. This division is also a reseller for Vehiclepath™ GPS Fleet and Asset Tracking products.

The Network Services Division provides the overall day-to-day maintenance and 24/7 monitoring of all wireless broadband networks that ERF Wireless constructs, acquires, maintains and administers. This division additionally provides project-level wireless broadband system design, construction and implementation.

On April 1, 2013, ERF Wireless announced that they filed their Form 10-K with the Securities and Exchange Commission (SEC) reporting results for the year ended December 31, 2012. Selected highlights include Revenues of $7,328,000 for the year ended December 31, 2012. This is in comparison to revenues of $5,320,000 for the same prior year ended December 31, 2011. This represents an increase of $2,008,000 or 38 percent.

They reported Gross Profit of $3,353,000 for the year ended December 31, 2012, versus $1,818,000 for the same prior year period ended December 31, 2011. This represents an increase of $1,535,000 or 84 percent. Additionally, they reported a total comprehensive loss of $4,821,000 for the year ended December 31, 2012, versus a total comprehensive loss of $3,404,000 for the same prior year ended December 31, 2011. This represents an increase of $1,417,000 or 42 percent.

ERF Wireless, Inc. (ERFB), closed Thursday's trading session at $0.70, up 11.11%, on 85,382 volume with 46 trades. The average volume for the last 60 days is 23,603 and the stock's 52-week low/high is $0.3651/$2.60.

Ghana Gold Corp. (GGCO)

SmallCapInvestorDaily, OTCtipReporter, PennyStockScholar, PennyStocks24, Penny Dreamers, Penny Trackers, InsideBulls, Penny Stock General, Center Stage Stocks, and HotStockProfits reported recently on Ghana Gold Corp. (GGCO), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Ghana Gold Corp. is a gold exploration and alluvial gold production company with properties in the Republic of Ghana. The Company has strategic land positions on the world-famous Ashanti Gold Belt. Ghana Gold's projects range from alluvial production to exploration of hard rock concessions. The Company is looking to expand their operations to other neighboring African countries that have promising gold mining opportunities. Ghana Gold is based in Garden City, New York.

The Company's Jukwa Concession is their first venture in Ghana. This expansive concession is in the Western Region on the western fringe of the Ashanti Gold Belt. Production yields have surpassed forecasts. Test results and production forecasts in a more favorable location at the northern tip of the concession have the Company's future projections exceeding current ratios. 

Ghana Gold's newest venture is Grumesa on the Ofin River. It is close to the village of Grumesa in the Ashanti Region. It is directly on the shores of the Ofin River. Infrastructure has been constructed and this project is very close to the world famous Anglo Gold Ashanti mine in Obuasi, Ghana.

The Company's projects also include the Offinso Gold Fields at Ahenkro. The project is 45 km northwest of Kumasi, Ghana's second largest city. The Ahenkro site is at the northern end of the Ashanti Gold Belt. The Ahenkro is 102.05 square kilometers. Ghana Gold also has their Brofoyedro project at the River Pra. The Brofoyedro is mid-way between Ghana's largest cities of Kumasi and the capital of Accra. The Company has options for up to 80 Small Scale Concessions with a land mass approaching 2,000 acres.

This week, Ghana Gold announced that they signed a Letter Of Intent (LOI) to acquire substantial mineral exploration, production and commercialization rights in the Central African Republic. The World Sports Alliance Intergovernmental Organization (WSA-IGO) will grant to Ghana Gold, mineral exploration, production and commercialization rights to significant gold concessions of the WSA-IGO. This is specifically in connection with the mining concession already granted by the Central African Republic, a member state of the WSA-IGO.

They will grant the rights to the mining concessions in such a way as to enable Ghana Gold to operate under the permits, agreements and approvals of the WSA-IGO. The terms of the LOI are to be confirmed in a mining rights acquisition agreement scheduled to be signed on or before April 20, 2013.

Ghana Gold Corp. (GGCO), closed Thursday's trading session at $0.032, even for the day, on 70,000 volume with 5 trades. The average volume for the last 60 days is 490,802 and the stock's 52-week low/high is $0.015/$12.00.

Gold Port Resources Ltd. (GPO.V)

Wyatt Investment Research and AllPennyStocks reported previously on Gold Port Resources Ltd. (GPO.V), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Listed on the TSX Venture Exchange, Gold Port Resources Ltd. is an exploration company focusing on Guyana, South America. They own the Groete Gold Copper Project. Exploration is directed by an experienced team situated in the country office in Georgetown, the capital of Guyana. Gold Port Resources has their corporate headquarters in Vancouver, British Columbia. The Company also has a U.S. exploration office in Bellingham, Washington.

The Groete Gold Copper Project is in the Cuyuni Mining District 4, approximately 60 kilometers southwest of Georgetown and close to the city of Bartica. Access is by way of a 16 km dirt road from Manaka, directly to the project area. The project is one of the most easily accessed large gold copper resources in Guyana. It has deep water and electrical power/support infrastructure within approximately 30 km. The Groete Gold Copper Project is 1538 hectares.

Gold Port Resources also holds a purchase option on the Georgetown West Gold Project. This project adjoins the Groete Gold Copper Project to the east. In addition, the Company is actively looking for additional properties elsewhere in Guyana that have the potential to enhance Gold Port's growth profile.

In March, the Company reported that they filed with SEDAR, a National Instrument 43-101 resource estimate and technical report. The report is titled "Technical Report and Resource Estimate on the Groete Gold Copper Deposit, Groete Property, Guyana, South America". It has an effective date of January 24, 2013. P & E Mining Consultants, Inc. of Brampton, Ontario, (P & E) independently prepared the report.

Highlights include an in-pit Inferred Resource of 1.59 million ounces at 0.66 grams per tonne gold equivalent (AuEq). This includes 0.49 g/t Au and 0.12 percent copper (Cu) contained in 74.8 million tonnes. A global sensitivity to the in-pit resource estimate (inside plus outside of pit) was calculated to be 2.0M AuEq ounces at 0.64 g/t AuEq. This includes 0.47 g/t Au and 0.11 percent Cu contained in 97.4 M tonnes

This week, Gold Port announced management and consultant appointments. Mr. William Feyerabend was appointed to the position of Qualified Person and a technical advisor to Gold Port Resources. Mr. Feyerabend has 30 years of experience at all levels of exploration and development with an emphasis on gold deposits. In addition, Mr. Tyler Friesen, C.A., was appointed to the position of Chief Financial Officer and Corporate Secretary to the Company.

Gold Port Resources Ltd. (GPO.V), closed Thursday's trading session at $0.035, down 22.22%, on 152,500 volume. The stock's 52-week low/high is $0.02/$0.08.

biOasis Technologies, Inc. (BTI.V)

We are reporting on biOasis Technologies, Inc. (BTI.V), here at the QualityStocks Daily Newsletter.

Based in Vancouver, British Columbia, biOasis Technologies, Inc. is a biopharmaceutical company whose business strategy focuses on out-licensing their technologies to qualified partners. Based on Transcend - biOasis proprietary brain delivery platform - the Company is concentrating on creating new drugs that can cross the blood-brain barrier (BBB) to address unmet medical needs in the treatment of brain diseases. These diseases include neurodegeneration, metastatic cancer and metabolic diseases.

biOasis Technologies' business strategy also emphasizes strategic acquisitions of products and technologies relevant to the diagnosis and management of Central Nervous System (CNS) diseases and disorders. Their Commercial Programs include Cognitest™ - a blood test designed to identify patients afflicted with Alzheimer's disease. Another program is Transcend™ - a carrier for delivery of therapeutic agents across the BBB.

Transcend-Herceptin® Conjugate (BT2111) is a conjugate between biOasis' Transcend brain delivery vector and trastuzumab (Herceptin®), a humanized monoclonal antibody used clinically in the treatment of HER2+ breast cancer. It is reported that up to 35 percent of HER2+ breast cancer patients develop brain metastasis for which therapeutic options are limited. biOasis is researching the potential of BT2111 for treatment of HER2+ metastatic breast cancer in the brain, because of its ability to deliver Herceptin® across the blood-brain barrier.

This past February, biOasis Technologies announced that they were named one of the 2013 TSX Venture 50® companies. The 2013 TSX Venture 50® includes the top 10 companies in five major industry sectors (mining, oil & gas, technology & life sciences, diversified industries and clean technology) that have been identified as leaders in providing shareholder value on Canada's junior stock exchange.

This week, biOasis Technologies announced an update on the advancement of their anti-cancer product candidate BT2111. Based on the outstanding data announced on February 7, 2013 that shows a significant reduction on brain tumors and tumor size, the Company, along with their expert industry advisors, has now developed the plan to take this program to the next stage of preclinical development.

biOasis Technologies, Inc. (BTI.V), closed Thursday's trading session at $1.25, up 9.65%, on 62,025 volume. The stock's 52-week low/high is $1.01/$2.13.

First Titan Corp. (FTTN)

PennyStocks24 reported recently on First Titan Corp. (FTTN), Blaque Capital Stocks, PennyStock PayCheck, Email Stock Picks, JackpotStock Picks, RagingStockBull, Penny Stock Market Bulls, Xtreme Stock Picks, StockMister, OTC Stock Pick did earlier, and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

First Titan Corp.'s commitment, via their wholly owned subsidiary, First Titan Energy, LLC, is to the exploration and development of oil and natural gas resources worldwide. They continually look to collaborate with energy developers that are pursuing unique new methods of oil and gas extraction. This includes the development of new technologies, cleaner methods and unconventional resources. First Titan is based in Florida; the Company lists on the OTC Market's OTCQB.

Currently, First Titan is evaluating numerous oil and gas asset acquisitions in Texas as potential additions to the working interests that the Company presently owns. Drilling preparations are now underway at their lease near South Lake Charles, Louisiana. Their horizontal well prospect, in Logan County, Oklahoma, is rigged up and set for completion. First Titan has partnered with Intrepid Drilling, LLC, a leader in oil and gas exploration and discovery.

Last week, First Titan announced that they hired Pimuro Capital Partners, LLC, to source and evaluate high-potential oil and gas opportunities on behalf of the Company. Pimuro Capital Partners possesses strong business ties throughout the U.S. energy sector. They will provide an extensive foundation of services to First Titan.

Earlier this week, First Titan announced that the Company is now going after new asset acquisitions and corporate mergers to facilitate additional expansion this spring. Chief Executive Officer, Mr. Harvey S. Bryant, said, "While we continue to build our oil and gas asset base, we are evaluating ancillary assets such as transportation infrastructure, marketing platforms and technological innovations that would further compliment the FTTN portfolio. We're particularly interested in working with individuals and companies who own oil and gas assets who would benefit from our development assistance and access to the public markets."

Today, the Company announced that they are in negotiations to acquire a working interest in approximately 1,000 acres in Hardin County, Texas. These properties include producing assets with development upside. These assets, located on the Texas Gulf Coast, are in a region that has been targeted by oil and gas companies for a number of decades.

First Titan Corp. (FTTN), closed Thursday's trading session at $0.55, up 22.22%, on 183,264 volume with 49 trades. The average volume for the last 60 days is 67,529 and the stock's 52-week low/high is $0.30/$11.00.

Sulliden Gold Corporation Ltd. (SUE.TO)

Streetwise Reports reported previously on Sulliden Gold Corporation Ltd. (SUE.TO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Sulliden Gold Corporation Ltd. is a precious metals company with corporate headquarters in Montreal, Quebec. The Company is focusing on the exploration and development of their wholly owned gold and silver Shahuindo Project (Peru). Sulliden Gold lists on the Toronto Stock Exchange (TSX) and on the premier tier of the U.S. Over-the-Counter (OTC) market (OTCQX) under the symbol "SDDDF".

The Company's Shahuindo Project is in a prolific gold producing district in northern Peru. A Feasibility Study was completed on this project in September 2012. It is a low cost, low capital mining project. The Company believes there is outstanding potential to increase the mineral resources at this project. Sulliden Gold, since 2009, has delivered two mineral resource updates, completed a Preliminary Economic Assessment (PEA) and the aforementioned Feasibility Study, and is currently in the advanced stage of permitting.

The Shahuindo property covers approximately 9,218 hectares (35 sq. miles) of mining concession. It additionally covers a further 10,795 hectares (41 sq. miles) on options at a good working elevation of ±2,900 meters. Neighboring low cash cost, million-ounce per year producing mines to Shahuindo include Barrick Gold's Lagunas Norte Mine - 30 kilometers to the south, and the Yanacocha Mine operated by Newmont - 80 kilometers to the north.

The Company also has their East Sullivan property in Canada. The East Sullivan property is approximately 8 kilometers to the southeast of the city of Val D’Or in the gold mining district of Abitibi, Quebec. The property consists of 21 adjacent and irregular claims. Sulliden Gold owns these 100 percent. These encompass a total area of approximately 334 hectares.

In March, Sulliden Gold provided a permitting update for their Shahuindo Project in Peru. On March 13, 2013, the Company successfully held and completed the final public audience as part of the Environmental and Social Impact Assessment (ESIA) process. The Federal Ministry of Energy and Mines (MINEM) moderated the meeting. All stakeholders received an invitation to participate. Sulliden Gold had strong community participation with more than 2,000 people attending. The completion of the public meeting marks the last required step before the ESIA approval.

Sulliden Gold Corporation Ltd. (SUE.TO), closed Thursday's trading session at $0.77, down 3.75%, on 771,166 volume. The stock's 52-week low/high is $0.68/$1.44.

Implant Sciences Corp. (IMSC)

Corporate Profile Team reported this week on Implant Sciences Corp. (IMSC), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.

Founded in 1984, Implant Sciences Corp. is the leader in next generation Explosives Trace Detection (ETD) technology. The Company is a high technology supplier of systems and sensors. They manufacture and sell sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. They've developed proprietary technologies used in their commercial explosive and narcotics trace detection systems. Implant Sciences is based in Wilmington, Massachusetts.

In January 2013, Implant Sciences became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. The Company's products undergo deployment globally to enhance the safety and security of their customers in areas including aviation security, force protection, subway security, customs and immigration, cargo security, critical infrastructure protection, ports and tunnels security, as well as VIP protection.

Implant Sciences develops and manufactures explosive trace detection sensors and systems capable of detecting minute amounts of a broad array of military, commercial, and homemade explosives. Their patented technologies provide unique screening capabilities to extend and improve counter-terrorist and homeland security efforts.

Their QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation. Implant Sciences' QS-B220 benchtop explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). It has also received TSA approval for air cargo screening. The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to quickly detect and identify trace amounts of a wide array of military, commercial, and homemade explosives, as well as drugs.

In March, the Company announced that they won a contract valued at approximately $585,000. This is for the sale of their Quantum Sniffer™ QS-H150 explosives trace detectors to a U.S. Government agency.

In addition, at the beginning of April, Implant Sciences announced that they have sold seven Quantum Sniffer™ QS-H150 handheld explosives trace detectors to a new customer in Africa. The units are to undergo deployment for security screening at court buildings and facilities.

Implant Sciences Corp. (IMSC), closed Thursday's trading session at $1.10, up 10.00%, on 676,349 volume with 302 trades. The average volume for the last 60 days is 327,980 and the stock's 52-week low/high is $0.70/$1.84.

graphic

The QualityStocks
Company Corner

graphic
graphic

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.023, up 15.00%, on 827,800 volume with 9 trades. The stock’s average daily volume over the past 60 days is 196,848, and its 52-week low/high is $0.001/$0.012.

Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.

Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.

In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Reaches Strategic Partnership Agreement With Knockout Gaming

Consorteum Holdings Inc. Reaches Funding Agreement With Private Equity Group

Consorteum Holdings Files Form 10-K Report With the Securities and Exchange Commission

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.269, up 3.46%, on 167,192 volume with 35 trades. The stock’s average daily volume over the past 60 days is 198,870, and its 52-week low/high is $0.161/$0.55.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation Announces Fourth Quarter 2012 Financial Results and Provides Business Update

International Stem Cell Corp. to Host Conference Call Thursday, March 28 to Discuss Year End 2012 Financial Results and Provide Business Update

International Stem Cell Corp. to Host Conference Call on Friday, March 22 to Discuss Positive Study Data of Parkinson's Disease

Advaxis, Inc. (ADXS)

The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.0875, up 1.74%, on 999,023 volume with 65 trades. The stock’s average daily volume over the past 60 days is 3,624,580, and its 52-week low/high is $0.0275/$0.155.

Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer

Advaxis, Inc. Company Blog

Advaxis, Inc. News:

Advaxis Announces Abstract Accepted for Oral Presentation at SITC Cancer Immunotherapy Clinical Trials Workshop

Advaxis Nominated for Best Early-Stage Vaccine Biotech at 6th Annual Vaccine Industry Excellence Awards

Advaxisí ADXS-cHER2 Immunotherapy Researchers Receive Penn One Health Award for Initiatives in Canine Osteosarcoma

Rainbow Coral Corp. (RBCC)

The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.11, off by 4.35%, on 136,731 volume with 26 trades. The stock’s average daily volume over the past 60 days is 168,790, and its 52-week low/high is $0.10/$2.67.

Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.

Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.

The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.

The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer

Rainbow Coral Corp. Company Blog

Rainbow Coral Corp. News:

RBCC Targets Companion Diagnostics Opportunities in Booming $232 Billion Personalized Medicine Market

RBCC: New Rainbow BioSciences Website Highlights Impressive Deal Flow

RBCC TheraKine Joint Venture Offers Significant Opportunity in Licensing

BG Medicine, Inc. (BGMD) Receives News of CE Mark for Galectin-3 Test

BG Medicine has received news that its partner Abbott, a global leader in in vitro diagnostics, has obtained a CE Mark for the Galectin-3 assay run on the ARCHITECT immunochemistry platform.

Pending country registration, this launch of the ARCHITECT Galectin-3 test under the CE Mark will make galectin-3 testing further available in several European countries – another significant step in BG Medicine’s commercial strategy. The progress made by Abbott will expand the use of galectin-3 testing in heart failure patients and strengthen BG Medicine’s ability to drive the growth of galectin-3 testing throughout the world. BG Medicine is currently partnering with four diagnostic instrument manufacturers in order to commercialize automated versions of the BGM Galectin-3 test.

Galectin-3 is a strong indicator of prognosis and readmission risk in heart failure patients. The availability of a rapid turnaround galectin-3 result would mean heart failure patients who are at high risk of adverse events can be identified more readily. Considering the rise in heart failure, it is important for new tools to be introduced that will aid fast clinical decision making processes and supply options for exploring new interventions.

In addition to Abbott, BG Medicine is also partnering with Alere, bioMérieux SA, and Siemens Healthcare Diagnostics to provide automated versions of its galectin-3 test to key market segments. bioMérieux SA launched the test earlier this year in Europe and certain other territories that recognize the CE Mark.

Galectin-3 testing has been implicated in various biological processes that are important in the development and progression of heart failure. Elevated levels of galectin-3 are associated with a more aggressive form of heart failure – potentially making the identification of high-risk patients using galectin-3 testing an important aspect of patient care. This testing may be useful in helping physicians identify those patients who are at a higher risk of death or hospitalization, including 30-day readmission.

For more information, visit www.bg-medicine.com or www.galectin-3.com

Autobytel Inc. (ABTL) Rolls Out Dealer of the Month Award

Autobytel, a company dedicated to helping automotive consumers and dealers connect online, has rolled out a brand new Dealer of the Month award program. The company chose Patti Scipione, Manager of M’Lady Nissan of Crystal Lake, Illinois, as its first-ever recipient for the month of March 2013.

Autobytel’s President and CEO, Jeffrey Coats, said, “Patti and the M’Lady Nissan team represent the best in online automotive sales and service. The benchmarks Autobytel created in 1995 when it pioneered the automotive Internet serve as the foundation upon which this entire industry operates today. Our longstanding history enables us to identify exceptional dealers who exceed the expectations of online automotive consumers and M’Lady Nissan does this time and again.”

Ms. Scipione remarked, “I’m really honored to be named Autobytel’s Dealer of the Month. I work with a great team of people who understand the importance of Internet customers and who make them a priority in our business. It`s a new generation of car buyers out there and you have to be willing to change with the times. Autobytel helps with these efforts by sending us the best quality customers compared to other lead providers.”

The Dealer Awards Program honors exceptional Autobytel dealers who demonstrate the highest standards in customer service, Internet automotive retail sales, and lead management processes.

Every month, Autobytel’s sales and dealer operations teams evaluate thousands of prospective candidates in the Autobytel network. The monthly finalist is selected based on key online automotive best practices and criteria, including conversion rates, lead management processes, customer service principles, customer and brand retention analytics, and Internet department practices.

The Autobytel Dealer Awards Program culminates at the NADA Convention & Expo in New Orleans in January 2014. The winner of this award will be chosen from this year’s monthly finalists. For more information about the Autobytel Dealer Awards Program, or to learn more about the winners, please visit www.dealer.autobytel.com.

Pluristem Therapeutics, Inc. (PSTI) Licensee Gets Regulatory Approval to Begin Phase I Study of PLX-PAD Cells

Pluristem Therapeutics is a leading developer of placenta-based cell therapies. The company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ishemic diseases. The cells are grown using the company’s proprietary 3D micro-environmental technology.

The company today announced that following favorable pre-clinical studies, biotechnology firm United Therapeutics Corp. received approval to perform a human Phase 1 study in Australia using Pluristem’s PLX-PAD cells in patients that have been diagnosed with pulmonary arterial hypertension (PAH). This disease is characterized by abnormally high blood pressure in the arteries of the lungs and leads to a greater workload for the right side of the heart.

United Therapeutics plans to conduct a single center, open-label, dose-escalation study in PAH patients. It plans to enroll up to 9 patients in three dosing levels with PLX-PAD cells administered intravenously. The main endpoint of the study is to evaluate the safety of PLX-PAD cells over the period of a year. There are also secondary efficacy endpoints at six week intervals.

In 2011, Pluristem and United Therapeutics entered into a licensing agreement where United Therapeutics will develop, market, and sell Pluristem’s PLX-PAD cells for PAH. Under terms of the agreement, United made an upfront payment of $7 million to Pluristem. Pluristem is also eligible to receive regulatory milestone and other payments that may total up to an additional $48 million. United bears all the costs of conducting the clinical trials.

The licensing agreement also provides that, following commercialization, United Therapeutics will buy the PLX-PAD product at a specified margin over Pluristem’s cost. In addition, United will pay Pluristem specified royalties as a percentage of its gross profits generated from the sale of the PLX-PAD cell products.

For further information about Pluristem Therapeutics and its PLX-PAD products, visit www.pluristem.com

Myriad Interactive Media, Inc. (MYRY) Establishes Entrance into European Market, Provides Mingle Suite Update

Myriad Interactive Media, an interactive media and development company in Canada, has expanded its global footprint to include Copenhagen, Denmark, where the company will sell Myriad and Mingle Suite technologies to the European market through a partnership with Opello Group ApS.

“We are delighted to announce that we have signed a joint-venture agreement with Opello Group ApS. Opello will manage the ‘Myriad’ brand in Denmark,” Derek Ivany, CEO of Myriad stated in the press release. “We have put together a strategic plan to expand our business to Europe and begin selling our Mingle Suite social media technology and Web site development solutions. Danish customers can now visit us live at www.myriadim.dk.”

Opello Group, based in Copenhagen, is a technology firm that develops customized Web solutions and provides personalized social engine optimization services, as well as hosting and other technology solutions.

Myriad also provided an update on its MingleSuite.com, a social media technology that synchs all social media accounts and leverages the traffic so businesses can improve their search engine rankings. The company has delayed the launch of its MingleSuite.com corporate Web site for about a week as it works to fill numerous backorders for the site’s services.

For more information visit www.myriadim.com

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

DrStockPick
(CLNO)

2.

Center Stage Stocks
(TRLR)

3.

PennyStockClub
(PLPE)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251